CULVER CITY, Calif.–(BUSINESS WIRE)– ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with multiple institutional investors, providing for the…Read More
ImmunityBio Announces Execution of 40 Million Equity Financing with Institutional Investors
